| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Epigenomics AG (OTCQX: EPGNY)
EPGNY Technical Analysis
5
| As on 19th Dec 2022 EPGNY STOCK Price closed @ 2.39 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 7.09 & Strong Sell for SHORT-TERM with Stoploss of 12.08 we also expect STOCK to react on Following IMPORTANT LEVELS. |
EPGNYSTOCK Price
| Open | 2.39 | Change | Price | % |
| High | 2.39 | 1 Day | 0.00 | 0.00 |
| Low | 2.39 | 1 Week | 0.00 | 0.00 |
| Close | 2.39 | 1 Month | 0.00 | 0.00 |
| Volume | N/A | 1 Year | -12.56 | -84.01 |
| 52 Week High 33.00 | 52 Week Low 2.29 | ||||
OTCQX USA Most Active Stocks
| KRRGF | 4.83 | 2.33% |
| FCUUF | 0.52 | -20.00% |
| ETHE | 27.50 | -3.34% |
| ZNOG | 0.16 | 6.67% |
| GBTC | 79.98 | 5.38% |
| EMHTF | 0.04 | 33.33% |
| SHIEF | 0.04 | 0.00% |
| GTBIF | 8.95 | 14.74% |
| FNGR | 3.22 | 1.90% |
| BABYF | 0.02 | -33.33% |
OTCQX USA Top Gainers Stocks
OTCQX USA Top Losers Stocks
| EPGNY Daily Charts |
EPGNY Intraday Charts |
Whats New @ Bazaartrend |
EPGNY Free Analysis |
|
|
EPGNY Important Levels Intraday
| RESISTANCE | 2.39 |
| RESISTANCE | 2.39 |
| RESISTANCE | 2.39 |
| RESISTANCE | 2.39 |
| RESISTANCE | 2.39 |
| RESISTANCE | 2.39 |
| RESISTANCE | 2.39 |
| RESISTANCE | 2.39 |
EPGNY Forecast May 2025
| 4th UP Forecast | 72.88 |
| 3rd UP Forecast | 50.27 |
| 2nd UP Forecast | 36.3 |
| 1st UP Forecast | 22.33 |
| 1st DOWN Forecast | -17.55 |
| 2nd DOWN Forecast | -31.52 |
| 3rd DOWN Forecast | -45.49 |
| 4th DOWN Forecast | -68.1 |
EPGNY Weekly Forecast
| 4th UP Forecast | 7.13 |
| 3rd UP Forecast | 5.61 |
| 2nd UP Forecast | 4.67 |
| 1st UP Forecast | 3.73 |
| 1st DOWN Forecast | 1.05 |
| 2nd DOWN Forecast | 0.11 |
| 3rd DOWN Forecast | -0.83 |
| 4th DOWN Forecast | -2.35 |
EPGNY Forecast2025
| 4th UP Forecast | 73.69 |
| 3rd UP Forecast | 50.82 |
| 2nd UP Forecast | 36.69 |
| 1st UP Forecast | 22.56 |
| 1st DOWN Forecast | -17.78 |
| 2nd DOWN Forecast | -31.91 |
| 3rd DOWN Forecast | -46.04 |
| 4th DOWN Forecast | -68.91 |
Epigenomics AG ( OTCQX USA Symbol : EPGNY )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
EPGNY Business Profile
Epigenomics AG, a molecular diagnostics company, focuses on blood testing for the early detection of cancer. Its lead product is Epi proColon(R), a blood-based test for the early detection of colorectal cancer in the United States, Europe, China. The company's products also include Hepatocellular carcinoma Blood Test, a blood test for cirrhotic patients at high-risk for the development of hepatocellular carcinoma; Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Address: Geneststrasse 5, Berlin, Germany, 10829
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service